|
Market Closed -
BME
11:35:28 2026-09-01 am EDT
|
5-day change | 1st Jan Change | ||
| 60.00 EUR | -0.99% |
|
-0.83% | -5.51% |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A., H1 2026 Earnings Call, Jul 23, 2026 | |
| Jul. 23 | Laboratorios Farmaceuticos Rovi, S.A. Reports Earnings Results for the Half Year Ended June 30, 2026 | CI |
Company Valuation: Laboratorios Farmaceuticos Rovi, S.A.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 4,138 | 1,925 | 3,213 | 3,220 | 3,248 | 3,069 | - | - |
| Change | - | -53.49% | 66.93% | 0.22% | 0.87% | -5.52% | - | - |
| Enterprise Value (EV) 1 | 4,112 | 1,872 | 3,251 | 3,305 | 3,272 | 3,052 | 2,987 | 2,875 |
| Change | - | -54.48% | 73.7% | 1.65% | -1% | -6.71% | -2.14% | -3.75% |
| P/E | 26.7x | 9.67x | 18.8x | 23.6x | 23.1x | 21.5x | 17.7x | 14.5x |
| PBR | 8.59x | 3.71x | 5.94x | 5.63x | 4.89x | 4.11x | 3.49x | 2.99x |
| PEG | - | 0.3x | -1.3x | -1.4x | 7.71x | 13.05x | 0.8x | 0.6x |
| Capitalization / Revenue | 6.38x | 2.35x | 3.87x | 4.22x | 4.37x | 3.98x | 3.44x | 3.14x |
| EV / Revenue | 6.34x | 2.29x | 3.92x | 4.33x | 4.4x | 3.96x | 3.35x | 2.95x |
| EV / EBITDA | 20.3x | 6.72x | 13.3x | 15.9x | 15.1x | 15.6x | 11.5x | 9.25x |
| EV / EBIT | 22.7x | 7.32x | 14.8x | 18.4x | 17.6x | 18.7x | 13.4x | 10.5x |
| EV / FCF | 37.9x | 10.1x | 54.3x | 43.5x | 27.4x | 16.6x | 24x | 17.4x |
| FCF Yield | 2.64% | 9.95% | 1.84% | 2.3% | 3.65% | 6.04% | 4.17% | 5.74% |
| Dividend per Share 2 | 0.9556 | 1.294 | 1.104 | 0.9351 | 0.9594 | 0.963 | 1.169 | 1.354 |
| Rate of return | 1.29% | 3.59% | 1.83% | 1.49% | 1.51% | 1.61% | 1.95% | 2.26% |
| EPS 2 | 2.76 | 3.73 | 3.2 | 2.67 | 2.75 | 2.795 | 3.388 | 4.146 |
| Distribution rate | 34.6% | 34.7% | 34.5% | 35% | 34.9% | 34.5% | 34.5% | 32.6% |
| Net sales 1 | 648.7 | 817.7 | 829.5 | 763.7 | 743.5 | 771.7 | 890.8 | 976.1 |
| EBITDA 1 | 202.9 | 278.7 | 244.5 | 207.4 | 216.2 | 196.3 | 258.6 | 310.9 |
| EBIT 1 | 181.5 | 255.8 | 220.1 | 179.4 | 185.8 | 163.5 | 223.7 | 274.4 |
| Net income 1 | 153.1 | 199.7 | 170.3 | 136.9 | 140.4 | 128.5 | 173.9 | 212.8 |
| Net Debt 1 | -25.87 | -52.78 | 38.6 | 85.1 | 23.84 | -16.21 | -81.51 | -193.5 |
| Reference price 2 | 73.80 | 36.06 | 60.20 | 62.95 | 63.50 | 60.00 | 60.00 | 60.00 |
| Nbr of stocks (in thousands) | 56,069 | 53,375 | 53,370 | 51,149 | 51,149 | 51,143 | - | - |
| Announcement Date | 2/23/22 | 2/21/23 | 2/27/24 | 2/25/25 | 2/24/26 | - | - | - |
1EUR in Million2EUR
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 21.68x | 4x | 15.71x | 1.59% | 3.6B | |
| 32.93x | 11.96x | 24.23x | 0.6% | 1,031B | |
| 29.57x | - | - | 2.02% | 641B | |
| 32.73x | 7.6x | 15.79x | 2.67% | 453B | |
| 19.66x | 4.67x | 11.58x | 2.83% | 349B | |
| 21.66x | 5.59x | 13.87x | 2.87% | 290B | |
| 20.88x | 4.29x | 12.24x | 2.06% | 252B | |
| 27.19x | 7.03x | 12.5x | 2.35% | 232B | |
| 13.11x | 4.72x | 9.86x | 3.87% | 201B | |
| -44.72x | 6.46x | 25.22x | 2.25% | 181B | |
| Average | 17.47x | 6.26x | 15.67x | 2.31% | 363.34B | |
| Weighted average by Cap. | 23.95x | 7.98x | 17.64x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROVI Stock
- Valuation Laboratorios Farmaceuticos Rovi, S.A.
Select your edition
All financial news and data tailored to specific country editions
